Salute e Benessere

Presagen's AI fertility product Life Whisperer acquired by Astec

The acquisition by Astec, with their strong global distribution network in the fertility sector, will accelerate the proliferation of this promising AI technology into IVF labs around the world. Astec also intends to make Life Whisperer a key feature of its embryo incubator product range. The acquisition by Astec, with their strong global distribution network in the fertility sector, will accelerate the proliferation of this promising AI technology into IVF labs around the world. Astec also...
PR Newswire
16/10/2024

Valneva and LimmaTech Awarded FDA Fast Track Designation for Tetravalent…

Saint Herblain (France) and Schlieren (Zurich), October 16, 2024 –Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, andLimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Shigella4V (S4V), the world's most clinically advanced tetravalent bioconjugate shigellosis vaccine candidate, for...
Nasdaq GlobeNewswire
16/10/2024

Radiation Oncology Market Size Worth $23.62 Billion, Globally, by 2031 -…

Overview of Report Findings Overview of Report Findings 1. Market Growth: The radiation oncology market is expected to reachUS$ 23.62 billionby 2031 fromUS$ 8.92 billionin 2023; it is anticipated to register a CAGR of 13.0% from 2023 to 2031. Radiation oncology is the specialized medical treatment of cancer using radiation therapy. Radiation oncology is high-energy radiation therapy with X-rays or high energy particles to kill cancer cells or shrink tumors. Radiation oncologists...
PR Newswire
16/10/2024

Mars announces new leadership for its Veterinary Health and Science &…

President of Mars Petcare, Loïc Moutault said: "I'm delighted that Nef will step up to lead our Veterinary Health business, working with 70,000 passionate, pet-loving Associates. She is a hugely talented leader with decades of complementary experience across health and services. I'm confident under Nef's leadership we will harness the knowledge, talent, and resources across our organization to support the veterinary profession and deliver world leading care for pets." President of…
PR Newswire
16/10/2024

Acquisition of Ovizio Imaging Systems SA

ANNOUNCEMENT NO. 280 16 October 2024Acquisition of Ovizio Imaging Systems SAOn the basis of the completed due diligence, ChemoMetec today submitted a binding tender offer for the acquisition of 100% of the shares of Belgian company Ovizio Imaging Systems SA ('Ovizio').The acquisition price is EUR 2,830,000.The tender offer has already been accepted by shareholders owning more than two thirds of Ovizio, and ChemoMetec is currently in the process of obtaining acceptance from the...
Nasdaq GlobeNewswire
16/10/2024

Upgrade of revenue and operating profit guidance

ANNOUNCEMENT NO. 279 16 October 2024Upgrade of revenue and operating profit guidance ChemoMetec sustained its positive performance in the first quarter of 2024/25 with better-than-expected sales and order intake.Based on this, the Company now expects revenue for the 2024/25 financial year in the DKK 445-460 million range, up from DKK 435-450 million in the most recent guidance, and EBITDA in the DKK 222-230 million range, up from DKK 216-223 million previously. ChemoMetec's...
Nasdaq GlobeNewswire
16/10/2024

Digital Dentures Market to Hit USD 2.16 Billion by 2029 with 8.7% CAGR |…

Browse in-depth TOC on "Digital Dentures Market" Browse in-depth TOC on "Digital Dentures Market" 318 - Tables58 - Figures274 - Pages The convenience of digital workflows, which streamline the entire process from impression taking to final denture fitting, and the increasing investments by key market players in research and development to introduce innovative products which is driving the market's growth. Based on type, the digital denture market is segmented into...
PR Newswire
16/10/2024

mRNA Synthesis & Manufacturing Market to Hit USD 738.3 Million by 2029 with 3.4%…

Browse in-depth TOC on "mRNA Synthesis & Manufacturing Market"250 - Tables50 - Figures250 - Pages Browse in-depth TOC on "mRNA Synthesis & Manufacturing Market" 250 - Tables 50 - Figures 250 - Pages The market is expanding rapidly due to factors such as the development of mRNA-based vaccines and expanded applications such as cancer immunotherapies. Furthermore, improvements in mRNA synthesis technology, a rise in mRNA synthesis and modification outsourcing, and…
PR Newswire
16/10/2024

Renovaro Announces Strategic Restructuring and Leadership Transition

Supermajority of Shareholders Support Appointment of New CEO and the Replacement of Entire Board of Directors with Full Five-Member SlateRealignment of Resources to Optimize and Commercialize RenovaroCube, the Company's Disruptive AI Platform for Multi-omics Diagnostics for Cancer Early Detection and Patient Monitoring from Liquid Biopsies Newly Appointed Board Encompass Seasoned Veterans from Capital Markets, Governance, AI, Biotechnology, Cancer Detection and Treatment...
Nasdaq GlobeNewswire
16/10/2024

Tanner Health and Healthliant Ventures Partner With Corti to Accelerate Medical…

Revolutionizing the Burden of Medical Coding Revolutionizing the Burden of Medical Coding "Healthcare systems are severely overburdened, with professionals spending almost 34 percent of their time on documentation," saidAndreas Cleve, CEO of Corti. "Our mission is to change this. Backed by over eight years of rigorous research, our peer-reviewed AI offers multiple models specifically built for healthcare so that it can be trusted to serve the industry's ultra complex and…
PR Newswire
16/10/2024

Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the…

“We are very pleased with the European Commission's grant of orphan medicinal product designation to VCN-01, emphasizing the urgent need for new treatment options for retinoblastoma,” said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics. “We have previouslyreportedencouraging results from an investigator sponsored Phase 1 trial evaluating the safety and activity of intravitreal VCN-01 in pediatric patients with refractory retinoblastoma, and we are working closely...
Nasdaq GlobeNewswire
16/10/2024

OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with…

Neuropathic corneal pain (NCP) is listed in the National Organization for Rare Disorders (NORD) as an orphan diseaseOKYO is the first company to have an IND application granted by the FDA for NCP The Phase 2 trial is designed as a randomized, placebo-controlled, double-masked study to treat 48 NCP patientsOK-101 demonstrated statistically significant pain relief in a recently completed Phase 2 trial of dry eye diseaseLONDON and NEW YORK, Oct.16, 2024(GLOBE NEWSWIRE) --...
Nasdaq GlobeNewswire
16/10/2024

Telix Featured in 13 Abstracts at the Annual Congress of the European…

Dr. David N. Cade, Telix Group Chief Medical Officer, said, "We are pleased to be able to so comprehensively showcase our pipeline at EANM – the largest gathering of nuclear medicine professionals worldwide – with a sponsored symposium, and abstracts accepted across Telix's late-stage theranostic programs in kidney and brain cancers, and in bone marrow conditioning. As in previous years, it is an honour for us to support the EANM Sanjiv Sam Gambhir Young Investigator Award. This is an…
PR Newswire
16/10/2024

Trading by management and close relations of management

Please see the attached PDF for details. Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes A/S, part of Novonesis Group reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. The released shares relate to the vesting of...
Nasdaq GlobeNewswire
16/10/2024

Biocomposites invests in InfectoTest GmbH - developers of a bacterial-specific…

The investment signifies Biocomposites' ongoing commitment to providing products for the management of infection in bone and soft tissue The investment signifies Biocomposites' ongoing commitment to providing products for the management of infection in bone and soft tissue KEELE,England , Oct. 16, 2024 /PRNewswire/ -- Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and...
PR Newswire
16/10/2024

XYRA Announces FDA Label Guidance for Managing Atrial Fibrillation with…

Phase 2 clinical data substantiates that XYRA's drug candidate, budiodarone, delivers significant reductions in symptoms, as well as the frequency and duration of AF episodes, among subjects with non-permanent AF which compare favorably to the results obtained with AF-ablation in a recent study. Upon reaching an agreement with the FDA regarding clinical trial endpoints and potential approval pathway for multiple active doses of budiodarone in the management of non-permanent AF, XYRA sought and…
PR Newswire
16/10/2024

GITEX DIGI_HEALTH 5.0 Dubai showcases the future of AI-driven innovations

- Tech enterprises and providers showcased the most impactful digital solutions to accelerate connectivity and drive transformation - Tech enterprises and providers showcased the most impactful digital solutions to accelerate connectivity and drive transformation DUBAI, UAE, Oct. 16, 2024 /PRNewswire/ -- Transformative health tech solutions were at the heart of conversations atGITEX GLOBAL'sGITEX DIGI_HEALTH 5.0Dubai, where thousands of tech enthusiasts and healthcare...
PR Newswire
16/10/2024

SKF to publish Q3 report on 30 October

To join the webcast, please login at least 10 minutes before the start using the below link or phone numbers: Link to web event: https://www.investis-live.com/skf/6703fe36b2cedb000e390899/aherus Sweden: +46 8 5051 0031 UK / International: +44 207 107 0613 To join the webcast, please login at least 10 minutes before the start using the below link or phone numbers:Link to web event:https://www.investis-live.com/skf/6703fe36b2cedb000e390899/aherus Sweden : +46 8 5051 0031UK /...
PR Newswire
16/10/2024

Essential Pharma Announces the Appointment of Dr Liz Holmes as Chief Medical…

Essential Pharma Announces the Appointment of Dr Liz Holmes as Chief Medical OfficerNewly established role at Essential Pharma further strengthens leadership team and supports global growth Dr Liz Holmes' rare disease and oncology expertise to be instrumental in bringing clinical stage immunotherapy asset Hu14.18 to marketEgham, UK – 16 October 2024– Essential Pharma, an international specialty pharma group focused on ensuring that patients have sustainable access to low volume,...
Nasdaq GlobeNewswire
16/10/2024

Tecan provides update on current trading and revised outlook for full year 2024

Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Tecan provides update on current trading and revised outlook for full year 2024 Substantial reductions in OEM customer forecasts as the main factor negatively impacting outlook for 2024 since last update in AugustLife Sciences Business continues to face a challenging market environment but is showing sequential growth in the second half of 2024Rigorous cost-down program being executed...
Nasdaq GlobeNewswire
16/10/2024

Olivier Falut appointed EUROAPI's Chief Financial Officer

Press Release Paris – October 16, 2024 –Olivier Falut has been appointed EUROAPI's Chief Financial Officer, effective October 17, 2024, and will be a member of the Executive Committee. He is taking over from Evelyne Nguyen, who will remain within the company until the end of October to ensure a smooth transition. “I am delighted to welcome Olivier, a seasoned Chief Financial Officer with extensive experience in the industrial sector. He will play a decisive role in...
Nasdaq GlobeNewswire
16/10/2024

New data on aprocitentan to be presented at the ASN Kidney Week 2024

Allschwil, Switzerland – October 16, 2024Idorsia Ltd (SIX: IDIA) today announced that new data on aprocitentan, Idorsia's endothelin receptor antagonist, will be presented at the American Society of Nephrology (ASN) Kidney Week 2024, taking place in San Diego, CA, October 23–27, 2024.The following oral and poster presentations will be held, highlighting the promising results of using aprocitentan for patients with hypertension not adequately controlled with other medications, with...
Nasdaq GlobeNewswire
16/10/2024

Metastatic Castration-Sensitive Prostate Cancer Clinical Trial Pipeline Insights…

Key Takeaways from the Metastatic Castration-Sensitive Prostate Cancer Pipeline Report Key Takeaways from the Metastatic Castration-Sensitive Prostate Cancer Pipeline Report Request a sample and discover the recent advances in mCSPC treatment drugs @ Metastatic Castration-Sensitive Prostate Cancer Pipeline Report The mCSPC pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage mCSPC drugs, inactive and dormant assets,...
PR Newswire
15/10/2024

AtomVie Global Radiopharma and Radiopharm Theranostics Partner to Develop and…

This collaboration brings together RAD's world-class platform of radiotherapeutic products and AtomVie's leading in manufacturing and distributing radiopharmaceuticals globally. 177Lu-BetaBart is part of a broader pipeline of distinct, highly differentiated technologies developed by RAD and RV. These span peptides, small molecules, and monoclonal antibodies for use in cancer, sourced from top-tier universities and institutes globally. The pipeline is designed with the strong potential to be…
PR Newswire
15/10/2024
Altri  Comunicati